A HPLC method for determination of nicousamide in dog plasma and its application to pharmacokinetic studies

A sensitive and reproducible high performance liquid chromatography (HPLC)-UV method for determination of nicousamide, an inhibitor of rennin and transforming growth factor-beta1 (TGF-β1) type II receptors, has been developed and validated. Following acetonitrile deproteiniation, samples were separated by isocratic reversed-phase HPLC on an Aichrom Bond-AQ C18 column and quantified using UV detection at 320 nm. The mobile phase was acetonitrile/water (ratio 62:38 containing 0.1% H3PO4), with a flow-rate of 1.0 ml/min. A linear curve over the concentration range 5–200 ng/ml (r2 = 0.9978) was obtained. The coefficients of the variation for the intra- and inter-day precisions ranged from 1.4–10.7% and 1.8–7.1%, respectively. The percentage of relative recovery was 91.56–105.45%. The method was used to determine the plasma concentration–time profiles for nicousamide after oral doses of 30, 100 and 300 mg/kg in dogs. A nonlinear pharmacokinetics was found in dogs at doses from 30 to 300 mg/kg. Following 30 mg/kg oral dose, the Cmax and AUC in females were lower than that in male. There is a potential for accumulation in dogs following multiple doses.